Sign In
Buy VCEL
$45.96
-1.65 (-3.47%)
At Close: Jul 31, 2026
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
08:30am, Wednesday, 26'th Oct 2022
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
08:30am, Thursday, 22'nd Sep 2022
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
08:30am, Tuesday, 06'th Sep 2022
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Compan
Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2022 Results - Earnings Call Transcript
02:57pm, Wednesday, 03'rd Aug 2022
Vericel Corporation (NASDAQ:VCEL ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colang
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
08:30am, Wednesday, 20'th Jul 2022
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will
Vericel Corp (VCEL) CEO Dominick Colangelo on Q1 2022 Results - Earnings Call Transcript
05:31pm, Wednesday, 04'th May 2022
Vericel Corp (NASDAQ:VCEL ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Eric Burns - Executive Director, Financial Planning and Analysis & IR Dominick Colangelo - CEO,
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
10:32am, Wednesday, 04'th May 2022
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel: Poised For Growth
08:49am, Sunday, 17'th Apr 2022
The NexoBrid complete response letter sparked a market overreaction on Vericel Corporation stocks. Coupled with the 2021/2022 Biotech Bear market, Vericel shares are trading at a deep bargain to their
Vericel - A Disruptive Business With Years Of Growth Remaining
11:34am, Tuesday, 12'th Apr 2022
Vericel is a high growth, disruptive medical technology company with average 5-year sales growth of 24%.
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
08:30am, Tuesday, 15'th Mar 2022
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick C
Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
08:30am, Tuesday, 01'st Mar 2022
CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick C
Vericel (VCEL) Q4 2021 Earnings Call Transcript
11:30pm, Thursday, 24'th Feb 2022 The Motley Fool
VCEL earnings call for the period ending December 31, 2021.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q4 2021 Results - Earnings Call Transcript
07:10pm, Thursday, 24'th Feb 2022 Seeking Alpha
Vericel Corporation 2021 Q4 - Results - Earnings Call Presentation
06:26pm, Thursday, 24'th Feb 2022 Seeking AlphaVericel Corporation (VCEL) CEO Nick Colangelo on Q4 2021 Results - Earnings Call Transcript
02:10pm, Thursday, 24'th Feb 2022
Vericel Corporation (VCEL) CEO Nick Colangelo on Q4 2021 Results - Earnings Call Transcript
